News

Read about the progress of individual NINDS PDBP projects and learn about presentations and workshops that are relevant to the PDBP.
High diagnostic value of plasma Niemann-Pick type C biomarkers in adults with selected neurological and/or psychiatric disorders.

  • Mandia D
  • Plaze M
  • Le Ber I
  • Ewenczyk C
  • Morin A
  • Carle G
  • Consoli A
  • Degardin A
  • Amad A
  • Moreau C
  • Anheim M
  • Tranchant C
  • Mélé N
  • Roue-Jagot C
  • Lagarde J
  • Sarazin M
  • Hamelin L
  • Ellul P
  • Pagan C
  • Pettazzoni M
  • Bekri S
  • Belliard S
  • Goizet C
  • Wallon D
  • Lamari F
  • Nadjar Y
A novel mutation in PSEN1 (p.Arg41Ser) in an Argentinian woman with early onset Parkinsonism.

  • Gatto EM
  • Rojas GJ
  • Nemirovsky SI
  • Da Prat G
  • Persi G
  • Cesarini M
  • Etcheverry JL
  • Rojas NG
  • Parisi V
  • Cordoba M
  • Sevlever G
  • Allegri RF
  • Turjanski AG
Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis.

  • Carlomagno C
  • Banfi PI
  • Gualerzi A
  • Picciolini S
  • Volpato E
  • Meloni M
  • Lax A
  • Colombo E
  • Ticozzi N
  • Verde F
  • Silani V
  • Bedoni M
Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy.

  • Santaella A
  • Kuiperij HB
  • van Rumund A
  • Esselink RAJ
  • Bloem BR
  • Verbeek MM
Glia-Derived Extracellular Vesicles in Parkinson's Disease.

  • Marchetti B
  • Leggio L
  • L'Episcopo F
  • Vivarelli S
  • Tirolo C
  • Paternò G
  • Giachino C
  • Caniglia S
  • Serapide MF
  • Iraci N
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies.

  • Graff-Radford J
  • Lesnick TG
  • Savica R
  • Chen Q
  • Ferman TJ
  • Przybelski SA
  • Jones DT
  • Senjem ML
  • Gunter JL
  • Kremers WK
  • Jack CR Jr
  • Lowe VJ
  • Petersen RC
  • Knopman DS
  • Boeve BF
  • Murray ME
  • Dickson DW
  • Kantarci K
Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution.

  • Ferman TJ
  • Aoki N
  • Boeve BF
  • Aakre JA
  • Kantarci K
  • Graff-Radford J
  • Parisi JE
  • Van Gerpen JA
  • Graff-Radford NR
  • Uitti RJ
  • Pedraza O
  • Murray ME
  • Wszolek ZK
  • Reichard RR
  • Fields JA
  • Ross OA
  • Knopman DS
  • Petersen RC
  • Dickson DW
Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.

  • Singer W
  • Schmeichel AM
  • Shahnawaz M
  • Schmelzer JD
  • Boeve BF
  • Sletten DM
  • Gehrking TL
  • Gehrking JA
  • Olson AD
  • Savica R
  • Suarez MD
  • Soto C
  • Low PA
Prospective Longitudinal Evaluation of Cytokines in mild cognitive impairment due to AD and Lewy Body Disease.

  • Thomas AJ
  • Hamilton CA
  • Donaghy PC
  • Martin-Ruiz C
  • Morris CM
  • Barnett N
  • Olsen K
  • Taylor JP
  • O'Brien JT
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach.

  • van Steenoven I
  • Koel-Simmelink MJA
  • Vergouw LJM
  • Tijms BM
  • Piersma SR
  • Pham TV
  • Bridel C
  • Ferri GL
  • Cocco C
  • Noli B
  • Worley PF
  • Xiao MF
  • Xu D
  • Oeckl P
  • Otto M
  • van der Flier WM
  • de Jong FJ
  • Jimenez CR
  • Lemstra AW
  • Teunissen CE

Press releases, workshop summaries, and editorials

NINDS Parkinson's Disease Biomarkers Program Consortium Meeting, Bethesda MD (August 12-13, 2019)

The PDBP Annual Consortium Meeting was held August 12-13, 2019 in Rockville, MD.  Principal investigators (PIs), clinical and data management experts from each PDBP project, and representatives from the  NIH, PD nonprofit organizations , and the pharmaceutical industry met to discuss progress over the last twelve months in addition to current and future plans for the program.

Accelerating Medicines Partnership launches data knowledge portal for Parkinson’s disease

Shared platform to catalyze research collaboration toward biomarker discovery to advance the development disease therapies

AMP PD

The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.